Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibition of peptic activity by carbenoxolone and glycyrrhetinic acid.

Literature DB >> 4913800

Inhibition of peptic activity by carbenoxolone and glycyrrhetinic acid.

Abstract

Carbenoxolone (Biogastrone, Berk) has been shown to reduce the peptic activity and total acidity of gastric juice obtained from anaesthetized pylorus-ligated rats without affecting significantly the volume of gastric juice secreted or the K(+) concentration. Glycyrrhetinic acid was less potent in reducing peptic activity and caused no reduction in total acidity. Antipeptic activity of carbenoxolone has also been demonstrated in vitro using the pepsin plate technique and the haemoglobin pepsin assay.It is suggested that these actions of carbenoxolone may contribute to the increased rate of healing of peptic ulcer in patients treated with the drug.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1970 PMID： 4913800 PMCID： PMC1411413 DOI： 10.1136/gut.11.4.344

Source DB: PubMed Journal: Gut ISSN： 0017-5749 Impact factor: 23.059

23 in total

1. TREATMENT OF GASTRIC ULCER WITH CARBENOXOLONE SODIUM AND OESTROGENS.

Authors: R DOLL; I D HILL; C F HUTTON
Journal: Gut Date: 1965-02 Impact factor: 23.059

2. The pharmacological properties of glycyrrhetinic acid hydrogen succinate (disodium salt).

Authors: R S FINNEY; A L TARNOKY
Journal: J Pharm Pharmacol Date: 1960-01 Impact factor: 3.765

3. The antiinflammatory activity of glycyrrhetinic acid and derivatives.

Authors: R S FINNEY; G F SOMERS
Journal: J Pharm Pharmacol Date: 1958-10 Impact factor: 3.765

4. The inhibition of the proteolytic action of pepsin by sulfate-containing polysaccharides.

Authors: S LEVEY; S SHEINFELD
Journal: Gastroenterology Date: 1954-11 Impact factor: 22.682

5. The nature of the binding of inhibitors to pepsin and the kinetics of inhibited peptic hydrolysis of N-acetyl-L-phenylalanyl-L-tyrosine.

Authors: M Schlamowitz; A Shaw; W T Jackson
Journal: J Biol Chem Date: 1968-05-25 Impact factor: 5.157

Review 3. Carbenoxolone sodium.

Authors: W Sircus
Journal: Gut Date: 1972-10 Impact factor: 23.059

Inhibition of peptic activity by carbenoxolone and glycyrrhetinic acid.

1. TREATMENT OF GASTRIC ULCER WITH CARBENOXOLONE SODIUM AND OESTROGENS.

2. The pharmacological properties of glycyrrhetinic acid hydrogen succinate (disodium salt).

3. The antiinflammatory activity of glycyrrhetinic acid and derivatives.

4. The inhibition of the proteolytic action of pepsin by sulfate-containing polysaccharides.

5. The nature of the binding of inhibitors to pepsin and the kinetics of inhibited peptic hydrolysis of N-acetyl-L-phenylalanyl-L-tyrosine.

6. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of spironolactone.

7. Carbenoxolone sodium in the treatment of gastric ulcer with special reference to side-effects.

8. Further experience with bismuth aluminate in peptic ulceration and nervous dyspepsia.

9. Biochemical effects of short-term treatment with carbenoxolone disodium.

10. Assessment of possible glucocorticoid activity of carbenoxolone sodium.

Review 1. Some aspects of medical management of gastrointestinal disease. I.

Review 2. Medical management of peptic ulcer with reference to anti-ulcer agents in other gastro-intestinal diseases.

Review 3. Carbenoxolone sodium.

Review 4. Cyclic GMP and gastric acid secretion.

5. Effect of carbenoxolone sodium on aspirin-induced injury of the rat gastric mucosa.

Review 6. Carbenoxolone: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.

7. Effects of carbenoxolone sodium on stress-induced gastric damage in rats.

8. Effects of carbenoxolone Na on acute and chronic gastric ulcer models in experimental animals.

9. Effect of carbenoxolone on the synthesis of glycoproteins and DNA in rat gastric epithelial cells.

10. Assessment of some Herbal Drugs for Prophylaxis of Peptic Ulcer.